

DEPARTMENT OF WAR

Defense Health Agency

Intent to Grant an Exclusive License for U.S. Government Owned Inventions

AGENCY: Defense Health Agency, DoW

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive, royalty-bearing, revocable, license within a field of use.

ADDRESSES: Commander, Defense Health Agency, Research and Development, ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. Rajendra Poudel, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license agreement to U.S. Patent Application 19/524,043 filed on October 10, 2024, and European Patent Application 24877988.6 filed October 10, 2024, entitled “Cerium Nitrate (CeN) – Silver Sulfadiazine (SSD) Barrier Foam” to ATD Emolda, having its principal place of business at Duboyne Industrial Estate, Dunboyne, Co. Meath, A86FP78, Ireland.

Anyone wishing to object to grant of this option can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections

are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).